Adverse Events After LP.8.1-Containing COVID-19 mRNA Vaccines

A nationwide cohort study of over 1.5 million adults in Denmark found no statistically significant increased risk of 30 adverse events within 28 days following vaccination with LP.8.1-containing COVID-19 mRNA vaccines.

The Gist

Imagine the Danish health authorities are like a massive, highly organized air traffic control tower. Their job is to watch over the sky (the population) to make sure that when new planes (vaccines) take off, they don't cause any unexpected turbulence or crashes.

In late 2025, a new type of plane called the LP.8.1 vaccine was introduced for older adults and those with health conditions. Before this new fleet took off, there were very few flight logs (safety data) to check. So, the control tower decided to run a massive, real-time simulation to see if these new planes were safe.

Here is what they found, broken down simply:

The Flight Plan (The Study)

The researchers looked at a huge group of 1.5 million people in Denmark who were 65 or older, or who had serious health issues. It's like checking the safety of a new car model by driving it with over a million different drivers on every type of road.

They focused on a specific window of time: the 28 days right after someone got the LP.8.1 shot. They compared what happened during those 28 days against what happened during "normal" times when people hadn't just gotten a shot. They looked for 30 specific types of medical trouble, ranging from heart issues to brain events, like a mechanic checking 30 different warning lights on a dashboard.

The Results: No Red Lights

After crunching the numbers, the "control tower" found no evidence of increased danger.

• The Heart Check: They worried about heart attacks or strokes. The data showed that the rate of these events after the shot was actually lower or the same as usual. For example, the risk of a heart event was about 95% of what it usually is (meaning no increase), and the risk of a stroke was even lower at 83%.
• The Muscle Check: They looked at heart inflammation (myocarditis), a rare but known concern with some vaccines. The data showed a tiny number of cases, but statistically, it was impossible to say the vaccine caused them. The "risk" number was so low it was basically a whisper in a hurricane.
• The Big Picture: Out of the 30 things they checked, none showed a statistically significant spike in problems after the vaccination.

The "Double-Check" System

To make sure they weren't missing anything, they used two different methods:

1. The Population Watch: Comparing the vaccinated group to the general population over time.
2. The "Time-Travel" Check (Self-Controlled Case Series): This is like looking at the same person's history and asking, "Did this person have more problems in the 28 days after the shot compared to the 28 days before?" This method is great because it cancels out personal quirks (like if someone is naturally prone to getting sick).

Both methods told the same story: No increased risk.

The Fine Print (What the Paper Actually Says)

The authors are careful to note a few things:

• It's a Snapshot: This study covers the period from July to December 2025. It doesn't predict what might happen in 2026 or beyond.
• Rare Events: Some bad things are so rare that even with 1.5 million people, it's hard to be 100% sure about the tiny numbers. However, the data is strong enough to say there are no big or moderate increases in risk.
• The "Healthy Vaccinee" Effect: Interestingly, some results suggested vaccinated people had fewer problems than usual. The authors suggest this might be because people who are sick enough to stay home don't go get vaccinated, so the group that does get vaccinated is naturally healthier at that moment. This isn't a "superpower" of the vaccine, just a quirk of who shows up to the clinic.

The Bottom Line

Think of the LP.8.1 vaccine as a new model of a car that passed a rigorous safety test with over a million drivers. The study found that for the 30 most critical safety checks, the new model performed just as well as, or better than, the standard expectation. There was no sign of a new, hidden danger lurking in the engine.

Technical Summary

Technical Summary: Adverse Events After LP.8.1-Containing COVID-19 mRNA Vaccines

Problem Statement
The LP.8.1-containing COVID-19 mRNA vaccines were recommended for the 2025 seasonal vaccination campaigns in Europe and the United States, specifically targeting individuals aged 65 years and older or those at high risk of severe COVID-19. Despite their deployment, safety data regarding these specific vaccine formulations remained limited. The study aimed to investigate the associations between LP.8.1-containing vaccines and the risks of 30 specific adverse events of special interest.

Methodology
The researchers conducted a nationwide register-based cohort study in Denmark utilizing linked health and demography registers.

• Cohort: The study included 1,565,697 adults aged 65 years or older, or those in high-risk groups who had received previous COVID-19 vaccine doses. The study period spanned from July 1, 2025, to December 3, 2025.
• Exposure: Vaccination status was classified in a time-varying manner. Of the cohort, 958,633 individuals received an LP.8.1-containing vaccine during the follow-up period.
• Outcomes: The study monitored 30 adverse events selected from prioritized lists of special interest for COVID-19 vaccines. Outcomes were identified as any first hospital contact where a specific diagnosis was recorded.
• Statistical Analysis:
  • Poisson Regression: Incidence rate ratios (IRRs) were estimated by comparing rates of adverse events within a 28-day risk period following vaccination against reference period rates (starting day 43 post-vaccination). Models were adjusted for age, sex, region of residence, high-risk status, calendar time, and the number of comorbidities.
  • Self-Controlled Case Series (SCCS): This complementary approach was employed to compare predefined risk and reference periods within the same individuals, inherently controlling for time-invariant confounders.
  • Significance: A 95% confidence interval (CI) not crossing 1 was defined as statistically significant. Analyses were conducted as surveillance activities by Statens Serum Institut and did not require ethics committee approval under Danish law.

Key Results
Among the 1.5 million participants (mean age 69.5 years; 53.8% female), the receipt of an LP.8.1-containing vaccine was not associated with a statistically significant increased rate of any of the 30 monitored adverse events within 28 days of vaccination compared to reference periods.

• Specific Findings:
  • Ischemic cardiac events: IRR 0.95 (95% CI, 0.86–1.06).
  • Cerebrovascular events: IRR 0.83 (95% CI, 0.76–0.92).
  • Myocarditis: IRR 0.32 (95% CI, 0.04–2.50).
• Consistency: Results from the SCCS analysis mirrored the Poisson regression findings, showing no statistically significant increased risks.
• Precision: While some outcomes were rare, leading to low statistical precision, the upper bounds of the 95% CIs for the majority of adverse events were inconsistent with moderate to large increases in relative risk. Some results suggested lower risks in vaccinated groups, potentially indicating a time-varying "healthy vaccinee effect."

Significance and Claims
The paper concludes that in a nationwide cohort of over 1.5 million adults, no increased risk of 30 adverse events was observed following vaccination with LP.8.1-containing COVID-19 mRNA vaccines. The authors assert that this finding holds across two complementary analytical approaches (Poisson regression and SCCS).

The authors maintain a modest tone regarding potential limitations, acknowledging that differences in adverse event ascertainment between periods cannot be excluded, though they argue such bias would likely favor increased risks rather than the observed null results. They further note that while the SCCS analysis reduces concerns about residual confounding, the lack of adjustment for multiple testing and the observation of lower risks in some vaccinated groups suggest that a healthy vaccinee effect cannot be ruled out. The study serves as a surveillance activity providing safety data for the 2025 seasonal campaign.